Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
J. Rodríguez, Ruth Zárate, Eva Bandrés, et al.
European Journal of Cancer (2012) Vol. 48, Iss. 12, pp. 1774-1780
Closed Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

Targeting natural killer cells in cancer immunotherapy
Camille Guillerey, Nicholas D. Huntington, Mark J. Smyth
Nature Immunology (2016) Vol. 17, Iss. 9, pp. 1025-1036
Closed Access | Times Cited: 977
Monoclonal Antibodies in Cancer Therapy
David J. Zahavi, Louis M. Weiner
Antibodies (2020) Vol. 9, Iss. 3, pp. 34-34
Open Access | Times Cited: 611
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
James D Mellor, Michael P. Brown, Helen Irving, et al.
Journal of Hematology & Oncology (2013) Vol. 6, Iss. 1
Open Access | Times Cited: 392
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier, Ariane Morel, Nadia Anceriz, et al.
Cell (2019) Vol. 177, Iss. 7, pp. 1701-1713.e16
Open Access | Times Cited: 359
Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
Ursula J. E. Seidel, Patrick Schlegel, Peter Lang
Frontiers in Immunology (2013) Vol. 4
Open Access | Times Cited: 230
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Wen-Qi Cai, Lisi Zeng, Lifeng Wang, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 147
Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
Cariad Chester, Katherine Fritsch, Holbrook E. Kohrt
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 162
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Robert L. Ferris, Heinz‐Josef Lenz, Anna Maria Trotta, et al.
Cancer Treatment Reviews (2017) Vol. 63, pp. 48-60
Open Access | Times Cited: 158
Targeting CD137 enhances the efficacy of cetuximab
Holbrook E. Kohrt, A. Dimitrios Colevas, Roch Houot, et al.
Journal of Clinical Investigation (2014) Vol. 124, Iss. 6, pp. 2668-2682
Open Access | Times Cited: 154
Genomics and emerging biomarkers for immunotherapy of colorectal cancer
Jakob Nikolas Kather, Niels Halama, Dirk Jaeger
Seminars in Cancer Biology (2018) Vol. 52, pp. 189-197
Open Access | Times Cited: 128
Innate immune mediators in cancer: between defense and resistance
Pedro Berraondo, Luna Minute, Daniel Ajona, et al.
Immunological Reviews (2016) Vol. 274, Iss. 1, pp. 290-306
Closed Access | Times Cited: 124
NK Cell-Based Immunotherapy in Cancer Metastasis
Seila Lorenzo‐Herrero, Alejandro López‐Soto, Christian Sordo‐Bahamonde, et al.
Cancers (2018) Vol. 11, Iss. 1, pp. 29-29
Open Access | Times Cited: 99
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
David J. Zahavi, Dalal Aldeghaither, Allison O’Connell, et al.
Antibody Therapeutics (2018) Vol. 1, Iss. 1, pp. 7-12
Open Access | Times Cited: 98
Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy
Anna Maria Trotta, Alessandro Ottaiano, Carmela Romano, et al.
Cancer Immunology Research (2016) Vol. 4, Iss. 4, pp. 366-374
Open Access | Times Cited: 74
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
Veena A. Thomas, Joseph P. Balthasar
Antibodies (2019) Vol. 8, Iss. 4, pp. 56-56
Open Access | Times Cited: 64
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs
Daphne Bertholee, Jan Gerard Maring, André B. P. Kuilenburg
Clinical Pharmacokinetics (2016) Vol. 56, Iss. 4, pp. 317-337
Open Access | Times Cited: 61
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
Andrew Charap, Tomohiro Enokida, Rachel Brody, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001523-e001523
Open Access | Times Cited: 51
Neutrophils as immune effector cells in antibody therapy in cancer
Leonie M. Behrens, Marjolein van Egmond, Timo K. van den Berg
Immunological Reviews (2022) Vol. 314, Iss. 1, pp. 280-301
Open Access | Times Cited: 30
Cancer immunotherapies: A hope for the uncurable?
Firas Hamdan, Vincenzo Cerullo
Frontiers in Molecular Medicine (2023) Vol. 3
Open Access | Times Cited: 17
Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies
Stefanie Derer, Philip Bauer, Stefan Lohse, et al.
The Journal of Immunology (2012) Vol. 189, Iss. 11, pp. 5230-5239
Open Access | Times Cited: 64
Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment
Holbrook E. Kohrt, Narendiran Rajasekaran, Cariad Chester, et al.
ImmunoTargets and Therapy (2015), pp. 91-91
Open Access | Times Cited: 53
Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies — Impact of effector cells
Shan Chung, Yuwen Linda Lin, Chae Reed, et al.
Journal of Immunological Methods (2014) Vol. 407, pp. 63-75
Closed Access | Times Cited: 53
Natural Killer Cells: A Review of Biology, Therapeutic Potential and Challenges in Treatment of Solid Tumors
Khalil Choucair, Joseph R. Duff, Christine S. Cassidy, et al.
Future Oncology (2019) Vol. 15, Iss. 26, pp. 3053-3069
Closed Access | Times Cited: 43
IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients
María P. Roberti, Yamila Rocca, Mora Amat, et al.
Breast Cancer Research and Treatment (2012) Vol. 136, Iss. 3, pp. 659-671
Closed Access | Times Cited: 52
ADCC: the rock band led by therapeutic antibodies, tumor and immune cells
Roos Vincken, Uxue Armendáriz-Martínez, Ana Ruiz-Sáenz
Frontiers in Immunology (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top